Immune Response to COVID-19 mRNA Vaccine—A Pilot Study

Twenty individuals (17 females, 3 males, aged 31–65 years (range), median: 46) who received both doses of the BioNTech Pfizer mRNA vaccine were examined (11 to 31 days, median: 25) after the second dose for the presence of antibodies against peptides of SARS-COV-2 and some of MERS-CoV, SARS-CoV1, HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Lange, Andrzej, Borowik, Agata, Bocheńska, Jolanta, Rossowska, Joanna, Jaskuła, Emilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150284/
https://www.ncbi.nlm.nih.gov/pubmed/34064613
http://dx.doi.org/10.3390/vaccines9050488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150284/
https://www.ncbi.nlm.nih.gov/pubmed/34064613
http://dx.doi.org/10.3390/vaccines9050488

Ejemplares similares